AnPac Bio-Medical Science Stock Forecast, Price & News

Wall Street analysts have given AnPac Bio-Medical Science a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AnPac Bio-Medical Science wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

AnPac Bio-Medical Science saw a drop in short interest in July. As of July 15th, there was short interest totaling 97,000 shares, a drop of 71.1% from the June 30th total of 335,400 shares. Based on an average trading volume of 1,020,000 shares, the short-interest ratio is currently 0.1 days.
View AnPac Bio-Medical Science's Short Interest.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) issued its quarterly earnings data on Thursday, May, 27th. The company reported ($0.37) EPS for the quarter. The company earned $0.33 million during the quarter.
View AnPac Bio-Medical Science's earnings history.

AnPac Bio-Medical Science's stock was trading at $8.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ANPC shares have decreased by 52.6% and is now trading at $4.03.
View which stocks have been most impacted by COVID-19.

Some companies that are related to AnPac Bio-Medical Science include Enzo Biochem (ENZ), Viridian Therapeutics (VRDN), Progenity (PROG), OpGen (OPGN), Vyant Bio (VYNT), Biocept (BIOC), CannLabs (CANL), Psychemedics (PMD), American Shared Hospital Services (AMS), American Shared Hospital Services (AMS), Avant Diagnostics (AVDX), CBA Florida (CBAI), First Choice Healthcare Solutions (FCHS), Zicix (ZICX) and Aeon Global Health (AGHC).
View all of ANPC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AnPac Bio-Medical Science investors own include Applied Genetic Technologies (AGTC), Aurora Cannabis (ACB), Adobe (ADBE), Advaxis (ADXS), Aptose Biosciences (APTO), Arcturus Therapeutics (ARCT), Ardelyx (ARDX), Ascendis Pharma A/S (ASND), Athenex (ATNX) and Aurinia Pharmaceuticals (AUPH).

(ANPC) raised $22 million in an initial public offering on the week of January 13th 2020. The company issued 1,700,000 shares at $12.00-$14.00 per share. WestPark Capital and Univest Securities acted as the underwriters for the IPO.

AnPac Bio-Medical Science trades on the NASDAQ under the ticker symbol "ANPC."

Shares of ANPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANPC stock can currently be purchased for approximately $4.03.

AnPac Bio-Medical Science has a market capitalization of $48.59 million and generates $3.14 million in revenue each year. The company earns $-12,330,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.

AnPac Bio-Medical Science employs 147,000 workers across the globe.

The official website for AnPac Bio-Medical Science is www.anpacbio.com.

AnPac Bio-Medical Science is headquartered at 801 BIXING STREET BIHU COUNTY ZHEJIANG PROVINCE, LISHUI F4, 323006.

AnPac Bio-Medical Science's mailing address is 801 BIXING STREET BIHU COUNTY ZHEJIANG PROVINCE, LISHUI F4, 323006. The company can be reached via phone at 86-578-2051-6666 or via email at [email protected]